Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Source:
Nasdaq GlobeNewswire
/
27 Nov 2023 06:00:00 America/Chicago
N/A
Share on,